Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES (GILD)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
Sector news Bio Therapeutic Drugs
04/19Novartis CEO feels heat on U.S. generics, Cosentyx drop
RE
04/12GSK slims portfolio with sale of rare disease gene therapy drugs
RE
04/12UK gene therapy firm Orchard plans stock offer after GSK deal
RE
04/12TAKEDA SOUNDS OUT BANKS FOR LOANS AS : sources
RE
04/12TAKEDA SOUNDS OUT BANKS FOR LOANS AS : sources
RE
04/12Takeda sounds out banks for loans as it moves towards Shire bid - sources
RE
04/10Novartis Deal to Help Drug Pipeline -- WSJ
DJ
04/10WHAT'S NEWS : Business & Finance -- WSJ
DJ
04/09Gene-Therapy Stocks Get Boost as Analysts Speculate Novartis' Next Target -- ..
DJ
04/09NOVARTIS : Buying AveXis for $8.7 Billion -- Deal Digest
DJ
04/09Novartis bets big on gene therapy with $8.7 billion AveXis deal
RE
04/09Novartis bets big on gene therapy with $8.7 billion AveXis deal
RE
04/09Novartis bets big on gene therapy with $8.7 billion AveXis deal
RE
04/09EUROPE MARKETS : European Stocks Rise To 2-week High
DJ
04/09NOVARTIS : Bets $8.7 Billion on Gene-Therapy Company -- Update
DJ
04/09NOVARTIS : Bets $8.7 Billion on Gene Therapy Company
DJ
04/09Novartis to Buy AveXis for $8.7 Billion -- Update
DJ
04/09NOVARTIS : to Buy AveXis for $8.7 Billion
DJ
04/09AVEXIS : Novartis AG to buy AveXis Inc for $8.7 billion
RE
04/06Incyte Shares Tumble After Cancer Drug Fails in Trial With Merck's Keytruda
DJ
03/21Britain's use of copycat biotech drugs takes off while U.S. lags
RE
03/11REGENERON PHARMACEUTICALS : and Sanofi Plan to Cut Cholesterol Drug Price in Exc..
DJ
03/10REGENERON PHARMACEUTICALS : and Sanofi Plan to Cut Cholesterol Drug Price in Exc..
DJ
02/15French pharma group Ipsen sees more asset purchases, U.S. growth
RE
02/14Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
RE
02/14BRISTOL MYERS SQUIBB : Nektar to Partner on Cancer Therapy
DJ
02/13Drug copies ready to take next bite out of Roche's cancer sales
RE
02/08REGENERON PHARMACEUTICALS : Collaborations Drive Revenue Increase at Regeneron -..
DJ
01/30Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom
RE
01/22Biotech M&A takes off as Sanofi and Celgene spend $20 billion
RE
01/22New drugs recast $10 billion haemophilia market as Sanofi swoops in
RE
01/12Drugmakers see a pricing blueprint in an $850,000 gene therapy
RE
01/08SANOFI : and Regeneron boost investment in cancer drug cemiplimab
RE
01/07ALNYLAM PHARMACEUTICALS : Sanofi Restructure RNAi Rare-Disease Alliance -- Updat..
DJ
01/07ALNYLAM PHARMACEUTICALS : Sanofi Restructure RNAi Rare-Disease Alliance
DJ
01/05Best week since April for European shares as UK, Swiss indexes hit records
RE
2017STOCKS TO WATCH : CSX, Aclaris, Alnylam, Rigel
DJ
2017ALNYLAM PHARMACEUTICALS : Stock Rises as FDA Lifts Study Hold
DJ
2017France's Sanofi pins hopes on new drugs after setbacks
RE
2017Sanofi investors hungry for drug progress and deal news
RE
2017Tax-loss selling to pressure 2017's losers in December
RE
2017GENMAB : and J&J 'love' partnership as some ponder takeover
RE
2017BIOGEN : Alkermes Join Forces for Multiple Sclerosis Drug
DJ
2017Regeneron drops eye-drug combination as Novartis chases Eylea
RE
2017BAYER : Amikacin Inhale Fails to Meet Objectives in Phase 3 Trial
DJ
2017Exclusive - Prescient messages about Indian companies circulate in WhatsApp g..
RE
2017Recovery rally for European stocks leaves oil sector behind
RE
2017Poor earnings updates keep European shares at seven-week low
RE
2017NOVARTIS : Vision Drug Shows Positive Results in Phase 3 Trials
DJ
2017Prosecutors search Metro offices in insider trading probe
RE
1  2  3  4  5  6  7  8  9  10Next
Financials ($)
Sales 2018 21 295 M
EBIT 2018 11 197 M
Net income 2018 6 715 M
Debt 2018 17 121 M
Yield 2018 3,11%
P/E ratio 2018 13,91
P/E ratio 2019 13,15
EV / Sales 2018 5,34x
EV / Sales 2019 5,47x
Capitalization 96 498 M